divider

News and Media

Publications and resources for members of the press.

divider

News

Sumitovant Biopharma Helps Identify More Than 80 Peptide Drug Candidates for Neochromosome’s Differentiated Manufacturing Technology

NEW YORK – January 19, 2023 – Sumitovant Biopharma, Inc. (“Sumitovant”), a technology-driven biopharmaceutical company accelerating the development and commercialization of novel therapeutics, announced it has identified more than 80 peptide drug candidates for manufacturing, using the company’s DrugOME™ computational platform. As part of a collaboration with Neochromosome, Inc. (“Neochromosome”), Sumitovant used extensive natural language […]

Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement

Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash Combination Provides Expertise and Resources to Address Unmet Patient Needs in Women’s Health and Prostate Cancer Agreement Unanimously Recommended by Special Committee of Myovant’s Independent Directors and Approved by Board NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 /PRNewswire/ — Sumitovant Biopharma Ltd. (“Sumitovant”), in conjunction with […]

Sumitovant Biopharma and Sumitomo Pharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences

NEW YORK and TOKYO October 2, 2022 — Sumitovant Biopharma Ltd. (“Sumitovant”), in conjunction  with parent company Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”), announced today it has  submitted a non-binding proposal (the “Proposal”) to the Audit Committee of the Board of Directors  (the “Audit Committee”) of Myovant Sciences Ltd. (“Myovant”) offering to acquire all outstanding […]

Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022

July 27, 2022 at 4:05 PM EDT First fiscal quarter 2022 total revenue of $116.5 million, including net product revenue of $41.4 million Net product revenue from U.S. sales of ORGOVYX® of $36.0 million in first fiscal quarter 2022, with sequential quarterly demand volume growth of 26% and cumulative patients estimated at 18,000 through June 2022 Net product revenue from U.S. sales of MYFEMBREE® of $4.0 million in […]

The Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities in the U.S. Highlighted in New Survey

July 13, 2022 at 8:00am PST Survey of 71 Directors of Nursing (DONs) highlights a need for improved awareness, education, and management of urinary incontinence (UI) related to overactive bladder (OAB) in long-term care (LTC) settings, according to this peer-reviewed journal paper. Surveyed DONs reported an average of 62% of their residents had UI, with 81% of […]

About Us

United in our mission to deliver breakthrough medicines to patients faster, we make Sumitovant greater than the sum of our parts.

Get to Know Us

News from Sumitovant Portfolio Companies